Cargando…
Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests
BACKGROUND: With rapid approval of SARS-CoV-2 vaccines, the ability of clinical laboratories to detect vaccine-induced antibodies with available high-throughput commercial assays is unknown. We aimed to determine if commercial serology assays can detect vaccine-induced antibodies (VIAs) and understa...
Autores principales: | Kanji, Jamil N., Bailey, Ashley, Fenton, Jayne, Ling, Sean H., Rivera, Rafael, Plitt, Sabrina, Sligl, Wendy I., Taylor, Sean, Turnbull, LeeAnn, Tipples, Graham, Charlton, Carmen L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354789/ https://www.ncbi.nlm.nih.gov/pubmed/34454782 http://dx.doi.org/10.1016/j.vaccine.2021.08.022 |
Ejemplares similares
-
mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations
por: Carreño, Juan Manuel, et al.
Publicado: (2022) -
Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
por: Kiewisz, Jolanta, et al.
Publicado: (2022) -
Toxic Epidermal Necrolysis after COVID-19 mRNA-1237 Vaccination
por: Hehr, Nicole, et al.
Publicado: (2023) -
Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022) -
Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)